Streetbeat News

Price Targets

SLN

Morgan Stanley analyst Michael Ulz has reiterated an Overweight rating on Silence Therapeutics (NASDAQ:SLN) and maintained a price target of $49.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 4:05 pm

PSX

Analysts have provided a range of ratings for Phillips 66 (NYSE:PSX) over the past three months, with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has decreased by 2.3% to $151.92. Recent analyst actions include both raises and lowers in ratings and price targets, reflecting changing market conditions and company performance. Phillips 66 has shown solid revenue growth and strong profitability metrics, with a conservative debt management approach.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 4:01 pm

MRVI

Maravai LifeSciences (NASDAQ:MRVI) has received mixed analyst ratings over the past three months, with a slight increase in the average 12-month price target. Analysts have varied in their ratings, with some lowering and others raising their price targets. The company has shown positive revenue growth and strong financial metrics, but faces challenges with a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 4:01 pm

CVX

UBS analyst Josh Silverstein has maintained a Buy rating on Chevron (NYSE:CVX) and raised the price target from $189 to $192.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 4:00 pm

ARMK

Analysts have provided mixed ratings for Aramark (NYSE:ARMK), with a recent positive shift in price targets. The average 12-month price target increased by 9.48% to $39.85. Analysts have raised their ratings, reflecting a more optimistic outlook. Despite this, Aramark's financial performance shows challenges, with below-average net margin, ROE, and ROA compared to industry peers.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 4:00 pm

BK

UBS analyst Brennan Hawken has maintained a Buy rating on Bank of New York Mellon (NYSE:BK) and increased the price target from $73 to $82.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 3:59 pm

BFAM

UBS analyst Joshua Chan maintains a Neutral rating on Bright Horizons Family Solutions (NYSE:BFAM) but raises the price target from $128 to $145.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 3:57 pm

AVNW

Lake Street analyst Jaeson Schmidt maintains a Buy rating on Aviat Networks but lowers the price target from $51 to $45.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 3:55 pm

MORN

Morningstar shares rose following UBS's initiation of coverage with a Buy rating and a $390 price target.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 3:50 pm

ARMK

UBS analyst Joshua Chan maintains a Buy rating on Aramark and raises the price target from $40 to $44.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 3:49 pm